Bayer's Nubeqa Meets Key Goal in Late-Stage Prostate Cancer Trial
By Adria Calatayud
Bayer's Nubeqa prostate cancer drug met its main goal in a late-stage trial, which the company said paves the way for regulatory submissions to extend the drug's uses.
The German pharmaceutical company said Wednesday that a Phase 3 clinical study that evaluated Nubeqa in combination with androgen deprivation therapy met its primary objective by increasing radiological progression-free survival in prostate cancer patients with metastasis.
The safety data of the trial confirmed the tolerability profile of the drug in advanced prostate cancer, the company said.
Bayer said it plans to prepare for regulatory submission with health authorities globally to expand the indication of the drug, which is already approved under the brand name Nubeqa for the treatment of patients with prostate cancer who are at high risk of developing metastatic disease and for those with metastatic hormone-sensitive prostate cancer.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 17, 2024 02:03 ET (06:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now